Healthcare - Biotechnology - NASDAQ - US
$ 0.46
2.68 %
$ 43.4 M
Market Cap
-1.35
P/E
CASH FLOW STATEMENT
-18.3 M
OPERATING CASH FLOW
-12 K
INVESTING CASH FLOW
27.5 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Unicycive Therapeutics, Inc.
| Net Income | -30.5 M |
| Depreciation & Amortization | 284 K |
| Capital Expenditures | -12 K |
| Stock-Based Compensation | 1.77 M |
| Change in Working Capital | -93 K |
| Others | 8.93 M |
| Free Cash Flow | -18.3 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | |
|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | ||||||
| Net Income | (30.5) | (18.1) | (10.0) | (2.3) | (2.2) | (1.1) |
| Depreciation & Amortization | 0.3 | 0.2 | 13 K | 0 | 0 | 0 |
| Deferred Income Tax | 0 | 0 | 0.1 | 0 | 0 | 0 |
| Stock Based Compensation | 1.8 | 1.0 | 1.0 | 0.2 | 24 K | 0 |
| Other Operating Activities | 10.3 | 21 K | 3.2 | 0.7 | 0.7 | 0.3 |
| Change in Working Capital | 93 K | 1.2 | (0.1) | (0.2) | 0.3 | 6 K |
| Cash From Operations | (18.3) | (15.7) | (5.8) | (1.5) | (1.2) | (0.8) |
| INVESTING CASH FLOW | ||||||
| Capital Expenditures | 12 K | 2 K | 29 K | 0 | 0 | 0 |
| Other Items | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash From Investing Activities | 12 K | 2 K | 29 K | 0 | 0 | 0 |
| FINANCING CASH FLOW | ||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 1.4 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 27.5 | (0.5) | 22.4 | (0.1) | 1.2 | 0.8 |
| Cash From Financing Activities | 27.5 | (0.5) | 22.4 | 1.4 | 1.2 | 0.8 |
| CHANGE IN CASH | ||||||
| Net Change In Cash | 9.2 | (16.1) | 16.6 | 15 K | 10 K | 25 K |
| FREE CASH FLOW | ||||||
| Free Cash Flow | (18.3) | (15.7) | (5.8) | (1.5) | (1.2) | (0.8) |